课题基金 / 基金详情

IGF::OT::IGF SUPPORT FOR HPV16L1/RG1 CHIMERIC VIRUS-LIKE PARTICLE VACCINE CLINICAL DEVELOPMENT TASKS 1&2 PP: 9/25/2015 TO 9/24/2018

IGF::OT::IGF SUPPORT FOR HPV16L1/RG1 CHIMERIC VIRUS-LIKE PARTICLE VACCINE CLINICAL DEVELOPMENT TASKS 1&2 PP: 9/25/2015 TO 9/24/2018
IGF::OT::IGF 支持 HPV16L1/RG1 嵌合病毒样颗粒疫苗临床开发任务 1
批准号:
9251710
负责人:
ALEXANDER LYUBIMOV
金额:
$57.79万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-09-25 至 2018-09-24

项目摘要

项目成果

ALEXANDER LYUBIMOV的其他基金

相似基金

相关文献

中文摘要
翻译
背景:目前上市的HPV疫苗可预防与高达90%的宫颈癌/粘膜癌相关的病毒类型感染(Guardasil 9)。为了潜在地扩大对所有HPV类型的保护。约翰霍普金斯大学的Richard Roden和维也纳医科大学的Reinhard Kirnbauer设计了一种嵌合hp16l1病毒样颗粒,该颗粒在VLP表面显示高度保守的L2免疫原性表位。临床前研究支持该疫苗对大量HPV类型的有效性。NCI prevention癌症临床前药物开发项目目前正在生产临床级HPV16L1/RG1嵌合VLP疫苗,用于非临床安全性和I期和II期概念验证测试。该产品将使用明矾/MPL作为佐剂,因此与Cervarix非常相似。虽然临床试验计划的细节仍在开发中,但预计I期试验将包括三种疫苗接种(0、2和6个月),并通过三个剂量水平(20、40和80µg)逐步增加剂量。
英文摘要
Background: Currently marketed HPV vaccines protect against infection by virus types associated with up to 90% of cervical/mucosal cancers (Guardasil 9). To potentially expand protection to all HPV types, Drs. Richard Roden, of Johns Hopkins University, and Reinhard Kirnbauer, of the Medical University of Vienna, have designed a chimeric HP16 L1 virus like particle that displays a highly conserved, immunogenic epitope of L2 on the surface of the VLP. Preclinical studies support the effectiveness of this vaccine against a large number of HPV types. The NCI PREVENT Cancer Preclinical Drug Development Program is currently producing clinical grade HPV16L1/RG1 chimeric VLP vaccine for non-clinical safety and Phase I and Phase II, proof of concept testing. The product will be adjuvanted with alum/MPL and thus very similar to Cervarix. While the details of the clinical testing plan are still under development, it is anticipated that the Phase I testing will involve three vaccinations (at 0, 2 and 6 months) with dose-escalation through three dose-levels (20, 40, and 80 µg).
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SUPPORT FOR HPV16L1/RG1 CHIMERIC VIRUS-LIKE PARTICLE VACCINE CLINICAL DEVELOPMENT TASKS 1&2
IGF::OT::IGF CONTRACT ORIENTATION AND KICKOFF MEETING 9/30/15 TO 12/31/2015
Task Order 7 - Nonclinical Toxicology Study of an investigational agent in development for anticancer therapy
Exploratory Toxicology Studies in Rats Administered MerTK - Task Order 04
海外基金